MAPK1 and cancer: Previous findings that CD44 can activate ERK [43, 44] and AKT [7, 38-42] and attenuate Hippo signaling [45] collectively suggest that CD44 may function as a common upstream regulator of these three pathways to favor cellular avoidance of contact inhibition in cancer cells.